We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
MRK.BA

Price
18525.00
Stock movement up
+575.00 (3.10%)
Company name
Merck & Company Inc
Exchange
(BA
,
Currency
ARS
)
Sector
Healthcare >
Drug Manufacturers - General
Markedsværdi
4831.61B
Ent værdi
4889.29B
Pris/omsætning
77.33
Pris/bog
110.69
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
58.13%
Efterfølgende P/E
351.75
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-40.40%
3 års afkast
72.98%
5 års afkast
63.28%
10 års afkast
74.25%
Senest opdateret: 2025-06-22

UDBYTTE

MRK.BA betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E351.75
Pris til OCF289.49
Pris til FCF367.51
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning77.33
Pris til egenkapital110.69
EV i forhold til salg78.25

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier252.96M
EPS (TTM)5.42
FCF pr. aktie (TTM)5.18

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)62.48B
Bruttofortjeneste (TTM)47.02B
Driftsindkomst (TTM)16.05B
Nettoindkomst (TTM)13.74B
EPS (TTM)5.42
EPS (1 år frem)-

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)75.25%
Driftsmargin (TTM)25.68%
Fortjenstmargin (TTM)21.98%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter11.30B
Nettotilgodehavender11.64B
Omsætningsaktiver i alt38.20B
Goodwill21.16B
Immaterielle aktiver16.98B
Ejendomme, anlæg og udstyr42.18B
Sum aktiver112.63B
Kreditor3.52B
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser26.06B
Sum gæld68.98B
Aktionærernes egenkapital43.65B
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)16.69B
Investeringsudgifter (TTM)3.54B
Fri pengestrøm (TTM)13.15B
Udbetalt udbytte (TTM)7.64B

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast31.47%
Afkast af aktiver12.20%
Afkast af investeret kapital17.53%
Kontant afkast af investeret kapital16.78%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning18650.00
Daglig høj19250.00
Daglig lav18075.00
Daglig volumen0K
Højeste gennem alle tider36375.00
1 års analytiker estimat-
Beta0.41
EPS (TTM)5.42
Udbytte pr. aktie-
Ex-div dato13 Jun 2025
Næste dato for resultatpræsentation29 Jul 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
MRK.BAS&P500
Nuværende prisfald fra top notering-49.07%-2.53%
Højeste prisfald-54.18%-56.47%
Højeste efterår dato13 Oct 20089 Mar 2009
Gennemsnitlig fald fra toppen-16.71%-11.04%
Gennemsnitlig tid til nyt højdepunkt5 days12 days
Maks. tid til nyt højdepunkt1350 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
MRK.BA (Merck & Company Inc) company logo
Markedsværdi
4831.61B
Markedsværdi kategori
Large-cap
Beskrivelse
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Personale
70000
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Argentina
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?
8. juli 2025
The Global Equine Healthcare Market is poised for robust growth, valued at USD 2.5 billion in 2024 and projected to reach USD 4.6 billion by 2034, growing at a CAGR of 6.3%. The surge in market growth...
8. juli 2025
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
8. juli 2025
Shareholders of 30 major corporations, collectively valued at more than $13 trillion, have voted overwhelmingly to reject anti-DEI proposals during 2025 proxy season, delivering a resounding defeat to...
8. juli 2025
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and qualityRADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CE...
8. juli 2025
RAHWAY, N.J., July 08, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be ...
8. juli 2025
Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product. The White House calls it "The Trump Effect" and features a roll...
8. juli 2025
An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide (https://ibn.fm/dyQrw) with these numbers expected to grow. The American...
7. juli 2025
EXEL surges 35.2% in three months as strong Cabometyx sales and zanzalintinib trial success fuel investor optimism.
7. juli 2025
Summit Therapeutics jumps 9% as AZN eyes a potential $15 billion licensing deal for its cancer drug, ivonescimab.
7. juli 2025
Næste side